Composition and methods for producing tobacco plants and products having reduced tobacco-specific nitrosamines (TSNAs)

US11634724B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11634724-B2
Application numberUS-202016838762-A
CountryUS
Kind codeB2
Filing dateApr 2, 2020
Priority dateOct 7, 2016
Publication dateApr 25, 2023
Grant dateApr 25, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides approaches for reducing tobacco-specific nitrosamines (TSNAs) in tobacco. Some of these approaches include genetically engineering tobacco plants to increase one or more antioxidants, increase oxygen radicle absorbance capacity (ORAC), or reduce nitrite. Also provided are methods and compositions for producing modified tobacco plants and tobacco products therefrom comprising reduced TSNAs.

First claim

Opening claim text (preview).

What is claimed is: 1. Cured leaf of a modified tobacco plant, wherein said cured leaf comprises a reduced level of one or more tobacco-specific nitrosamines (TSNAs), an increased amount of protein activity in a protein comprising a sequence having at least 90% identity to SEQ ID NO: 13, and further comprises an increased level of one or more antioxidants, wherein said reduced and increased levels are compared to a control cured leaf of an unmodified tobacco plant of the same variety when grown and cured under comparable conditions; and wherein said increased amount of protein activity is a result of the modification in said modified tobacco plant. 2. A tobacco product comprising the cured leaf of claim 1 . 3. The cured leaf of claim 1 , wherein said cured leaf comprises an increased level of oxygen radical absorbance capacity (ORAC) compared to said control cured leaf. 4. The cured leaf of claim 1 , wherein said cured tobacco leaf comprises less than 2 ppm total TSNAs. 5. The cured leaf of claim 1 , wherein said cured tobacco leaf comprises less than 0.08 ppm 4-methylnitrosoamino-1-(3-pyridyl)-1-butanone (NNK), wherein the level of said total TSNAs is measured based on a freeze-dried cured leaf sample using liquid chromatograph with tandem mass spectrometry (LC/MS/MS). 6. The cured leaf of claim 1 , wherein said one or more antioxidants are selected from the group consisting of anthocyanidin, flavanone, flavanol, flavone, flavonol, isoflavone, hydroxybenzoic acid, hydroxycinnamic acid, ellagitannin, stibene, lignan, carotenoids, and glycyrrhzin. 7. The cured leaf of claim 1 , wherein said one or more tobacco-specific nitrosamines (TSNAs) are selected from the group consisting of N′-nitrosonornicotine (NNN), 4-methylnitrosoamino-1-(3-pyridyl)-1-butanone (NNK), N′-nitrosoanatabine (NAT), and any combination thereof. 8. The cured leaf of claim 1 , wherein said modified tobacco plant is selected from the group consisting of a flue-cured variety, a Burley variety, a Maryland variety, a dark variety, and an Oriental variety. 9. The cured leaf of claim 1 , wherein said modification in said modified tobacco plant comprises a tobacco genome mutation or a transgene. 10. The cured leaf of claim 9 , wherein the level of said one or more TSNAs is reduced by at least 50% compared to cured tobacco leaf or a tobacco product from a control tobacco plant not comprising said transgene or said genetic modification. 11. The cured leaf of claim 9 , wherein said transgene encodes a protein comprising a sequence having at least 95% identity to SEQ ID NO. 13. 12. Cured leaf of a modified tobacco plant, wherein said cured leaf comprises a reduced level of nitrite, an increased amount of protein activity in a protein comprising a sequence having at least 90% identity to SEQ ID NO: 13, comprises an increased level of one or more antioxidants, wherein said reduced and increased levels are compared to a control cured leaf of an unmodified tobacco plant of the same variety when grown and cured under comparable conditions; and wherein said increased amount of protein activity is a result of the modification in said modified tobacco plant. 13. A tobacco product comprising the cured leaf of claim 12 . 14. The cured leaf of claim 12 , wherein said cured leaf comprises an increased level of oxygen radical absorbance capacity (ORAC) compared to said control cured leaf. 15. The cured leaf of claim 12 , wherein said cured tobacco leaf comprises less than 2 ppm total TSNAs. 16. The cured leaf of claim 15 , wherein said cured tobacco leaf comprises less than 0.08 ppm 4-methylnitrosoamino-1-(3-pyridyl)-1-butanone (NNK), wherein the level of said total TSNAs is measured based on a freeze-dried cured leaf sample using liquid chromatograph with tandem mass spectrometry (LC/MS/MS). 17. The cured leaf of claim 12 , wherein said cured leaf comprises a reduced level of one or more tobacco-specific nitrosamines (TSNAs) selected from the group consisting of N′-nitrosonornicotine (NNN), 4-methylnitrosoamino-1-(3-pyridyl)-1-butanone (NNK), N′-nitrosoanatabine (NAT), and any combination thereof. 18. The cured leaf of claim 12 , wherein said modified tobacco plant is selected from the group consisting of a flue-cured variety, a Burley variety, a Maryland variety, a dark variety, and an Oriental variety. 19. The cured leaf of claim 12 , wherein said modification in said modified tobacco plant comprises a tobacco genome mutation or a transgene. 20. The cured leaf of claim 19 , wherein the level of nitrite is reduced by at least 50% compared to cured tobacco leaf or a tobacco product from a control tobacco plant not comprising said transgene or said genetic modification. 21. The cured leaf of claim 19 , wherein said transgene encodes a protein comprising a sequence having at least 95% identity to SEQ ID NO. 13.

Assignees

Inventors

Classifications

  • Motors · CPC title

  • Mixing by a special element, e.g. stirrer · CPC title

  • with means for piercing stoppers or septums · CPC title

  • Diluting, dispersing or mixing samples · CPC title

  • mechanically breaking a wall or membrane within a channel or chamber · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11634724B2 cover?
The present disclosure provides approaches for reducing tobacco-specific nitrosamines (TSNAs) in tobacco. Some of these approaches include genetically engineering tobacco plants to increase one or more antioxidants, increase oxygen radicle absorbance capacity (ORAC), or reduce nitrite. Also provided are methods and compositions for producing modified tobacco plants and tobacco products therefro…
Who is the assignee on this patent?
Altria Client Services Llc
What technology area does this patent fall under?
Primary CPC classification C12N15/8243. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).